June 7, 2021

Recent approval by U.S. regulators of a drug to treat Alzheimer’s disease (Aducanumab) lifted shares of companies developing treatments for the mind wasting disease. Our Kevin Gade told Reuter’s News, “The biotech sector needed a spark and this was an explosion.”

Kevin T. Gade, CFA, CFP
Portfolio Manager
kgade@bahl-gaynor.com

Read the full article HERE (a subscription may be required).